IP Library › Granted Patent US 9,221,866

Granted Patent B2

US 9,221,866 · App. 14/560,097 · Granted Dec 29, 2015

Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer

Inventors: Christopher McGuigan (Cardiff, GB); Jan Balzarini (Heverlee, BE); Magdalena Slusarczyk (Cardiff, GB); Blanka Gonczy (Cardiff, GB); Paola Murziani (Cardiff, GB)

Assignee: NuCana Biomed Limited

C07H19/10 A61K31/7072 A61K45/06 C07F9/65515 C07F9/65586 C07F9/65844

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,221,866
App. No.: 14/560,097
Granted: Dec 29, 2015
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma -infected cells and/or with cells with a raised level of thymidylate synthase.

Claims (165)

1. A compound of formula (I):

wherein

Ar is a fused bicyclic aryl moiety or a monocyclic aryl moiety, either of which aryl moieties is carbocyclic or heterocyclic and is optionally substituted;

R 3 is alkyl, which is optionally substituted;

R 4 is H or alkoyl;

R 1 and R 2 are independently selected from the group consisting of H and alkyl, or R 1 and R 2 together form an alkylene chain so as to provide, together with the C atom to which they are attached, a cyclic system, or one of R 1 and R 2 comprises an alkylene chain attached to N, the H atom attached to N is absent and one of R 1 and R 2 comprise H or alkyl, any of which said alkyl moieties or alkylene chains is optionally substituted;

or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound of formula (I),

wherein the compound is not a compound having, in combination, Ar as unsubstituted phenyl, R 3 as CH 3 , R 4 as H, one of R 1 and R 2 as H and one of R 1 and R 2 as CH 3 .

2. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein Ar is naphthyl.

3. The compound according to claim 2 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein Ar is 1-naphthyl.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein Ar is phenyl.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein Ar is substituted.

6. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein R 4 is selected from the group consisting of H and acetyl.

7. The compound according to claim 6 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 6 , wherein R 4 is H.

8. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein R 3 is selected from the group consisting of benzyl and members of the group comprising C 1 to C 10 alkyls.

9. The compound according to claim 8 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 8 , wherein R 3 is ethyl, n-propyl, n-butyl, n-pentyl, or n-hexyl.

10. The compound according to claim 9 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 9 , wherein R 3 is n-pentyl.

11. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein R 1 and R 2 are different and the stereochemistry at the asymmetric centre —CR 1 R 2 corresponds to an L-amino acid or a D-amino acid.

12. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein R 1 and R 2 correspond to the moieties attached to the alpha C atom in a natural occurring alpha amino acid.

13. The compound of claim 12 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 12 , wherein the natural occurring alpha amino acid is L-alanine.

14. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein Ar is 1-naphthyl, R 3 is benzyl, and one of R 1 and R 2 is H, one of R 1 and R 2 is methyl and the C atom to which R 1 and R 2 are attached has L-chirality.

15. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , wherein Ar is 1-naphthyl, R 3 is n-pentyl, one of R 1 and R 2 is H, one of R 1 and R 2 is methyl and the C atom to which R 1 and R 2 are attached has L-chirality.

16. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , which is selected from:

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy- L -alaninyl)]phosphate (CPF 381);

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(ethoxy- L -alaninyl)]phosphate (CPF383);

5-Fluoro-2′deoxyuridine-5′-O-[phenyl(isopropoxy- L -alaninyl)]phosphate (CPF384);

5-Fluoro-2′deoxyuridine-5′-O-[phenyl(cyclohexoxy- L -alaninyl)]phosphate (CPF508);

5-Fluoro-2′deoxyuridine-5′-[p-nitro-phenyl(ethoxy- L -alaninyl)]phosphate (CPF430);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(benzoxy- L -alaninyl)]phosphate (CPF373);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(methoxy- L -alaninyl)]phosphate (CPF385);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(ethoxy- L -alaninyl)]phosphate (CPF386);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(isopropoxy- L -alaninyl)]phosphate (CPF387);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(cyclohexoxy- L -alaninyl)]phosphate (CPF509);

5-Fluoro-2′deoxyuridine-5′-O-[phenyl(benzoxy-α,α-dimethylglycine)]phosphate (CPF393);

5-Fluoro-2′deoxyuridine-5′-O-[phenyl(ethoxy-α,α-dimethylglycine)]phosphate (CPF394);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(benzoxy-α,α-dimethylglycine)]phosphate (CPF395);

5-Fluoro-2′deoxyuridine-5′-O-[1-naphthyl(ethoxy-α,α-dimethylglycine)]phosphate (CPF396);

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy-L-prolinyl)]phosphate (CPF583);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(benzoxy-L-prolinyl)]phosphate (CPF577);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(3,3-dimethyl-1-butoxy- L -alaninyl)]phosphate (CPF585);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(cyclobutoxy-L-alaninyl)]phosphate (CPF578);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(cyclopropylmethanoxy-L-alaninyl)]phosphate (CPF579);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(tetrahydropyroxy-L-alaninyl)]phosphate (CPF580);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(pentoxy-L-alaninyl)]phosphate (CPF581);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(cyclopentoxy-L-alaninyl)]phosphate (CPF582);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(2-indanoxy-L-alaninyl)]phosphate (CPF597);

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl-(benzoxy-L-methioninyl)]phosphate (CPF586);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(benzoxy-L-phenylalaninyl)]phosphate (CPF587);

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)]phosphate (CPF588); and

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl-(butoxy-L-alaninyl)]phosphate (CPF589).

17. A method of treatment of cancer, wherein the cancer is selected from leukemia, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and cervical cancer, comprising administering to a Homo sapiens patient in need of such treatment an effective dose of a compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 .

18. A method of treatment of cancer, wherein the cancer is selected from oesophageal cancer, gastrointestinal cancer, head and neck cancer, and ovarian cancer, comprising administering to a Homo sapiens patient in need of such treatment an effective dose of a compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 .

19. The method according to claim 17 further comprising treatment of said patient with other cancer therapy.

20. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , in combination with a pharmaceutically acceptable carrier, diluent or excipient.

21. A method of preparing a pharmaceutical composition comprising the step of combining a compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , with a pharmaceutically acceptable excipient, carrier or diluent.

22. The compound according to claim 1 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 1 , selected from:

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(ethoxy-L-valinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy-L-leucinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy-L-isoleucinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy-L-phenylalaninyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(pentoxy-L-methioninyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(hexoxy-L-alaninyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(cyclohexoxy-L-valinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(pentoxy-L-leucinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(benzoxy-L-leucinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(pentoxy-L-isoleucinyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(pentoxy-L-phenylalaninyl)]phosphate;

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(benzoxy-L-methioninyl)]phosphate; and

5-Fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(pentoxy-α,α-dimethylglycine)]phosphate.

23. A method of treatment of cancer, wherein the cancer is selected from leukemia, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and cervical cancer, comprising administering to a Homo sapiens patient in need of such treatment an effective dose of a compound according to claim 22 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 22 .

24. A method of treatment of cancer, wherein the cancer is selected from oesophageal cancer, gastrointestinal cancer, head and neck cancer, and ovarian cancer, comprising administering to a Homo sapiens patient in need of such treatment an effective dose of a compound according to claim 22 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 22 .

25. A pharmaceutical composition comprising a compound according to claim 22 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 22 , in combination with a pharmaceutically acceptable carrier, diluent or excipient.

26. A method of preparing a pharmaceutical composition comprising the step of combining a compound according to claim 22 , or a pharmaceutically acceptable salt, ester, salt of such ester, hydrate, solvate, crystalline form, or metabolite thereof, or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) said compound according to claim 22 , with a pharmaceutically acceptable excipient, carrier or diluent.

27. A process for the preparation of a compound of formula (I) according to claim 1 , the process comprising reacting a compound of formula (II)

with a compound of formula (III)

wherein Ar, R 3 , R 4 , R 1 and R 2 have the meanings described in claim 1 .

28. The method of claim 17 wherein said cancer is breast cancer.

29. The method of claim 17 wherein said cancer is lung cancer.

30. The method of claim 18 wherein said gastrointestinal cancer is selected from gastric cancer, small intestine cancer, and colon and rectum cancer.

31. The method of claim 18 wherein said gastrointestinal cancer is colon and rectum cancer.

32. The method of claim 23 wherein said cancer is breast cancer.

33. The method of claim 23 wherein said cancer is lung cancer.

34. The method of claim 24 wherein said gastrointestinal cancer is selected from gastric cancer, small intestine cancer, and colon and rectum cancer.

35. The method of claim 24 wherein said gastrointestinal cancer is colon and rectum cancer.

36. A compound of formula (I):

wherein

Ar is a fused bicyclic aryl moiety or a monocyclic aryl moiety, either of which aryl moieties is carbocyclic or heterocyclic and is optionally substituted;

R 3 is alkyl, which is optionally substituted;

R 4 is H or alkoyl;

or a pharmaceutically acceptable salt thereof,

wherein the compound is not a compound having, in combination, Ar as unsubstituted phenyl, R 3 as CH 3 , R 4 as H, one of R 1 and R 2 as H and one of R 1 and R 2 as CH 3 .

37. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein Ar is naphthyl.

38. The compound according to claim 37 , or a pharmaceutically acceptable salt thereof, wherein Ar is 1-naphthyl.

39. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl.

40. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein Ar is substituted.

41. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of H and acetyl.

42. The compound according to claim 41 , or a pharmaceutically acceptable salt thereof, wherein R 4 is H.

43. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of benzyl and members of the group comprising C 1 to C 10 alkyls.

44. The compound according to claim 43 , or a pharmaceutically acceptable salt thereof, wherein R 3 is ethyl, n-propyl, n-butyl, n-pentyl, or n-hexyl.

45. The compound according to claim 44 , or a pharmaceutically acceptable salt thereof, wherein R 3 is n-pentyl.

46. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are different and the stereochemistry at the asymmetric centre —CR 1 R 2 corresponds to an L-amino acid or a D-amino acid.

47. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 correspond to the moieties attached to the alpha C atom in a natural occurring alpha amino acid.

48. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the natural occurring alpha amino acid is L-alanine.

49. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein Ar is 1-naphthyl, R 3 is benzyl, and one of R 1 and R 2 is H, one of R 1 and R 2 is methyl and the C atom to which R 1 and R 2 are attached has L-chirality.

50. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, wherein Ar is 1-naphthyl, R 3 is n-pentyl, one of R 1 and R 2 is H, one of R 1 and R 2 is methyl and the C atom to which R 1 and R 2 are attached has L-chirality.

51. The compound according to claim 36 , or a pharmaceutically acceptable salt thereof, which is selected from:

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy- L -alaninyl)]phosphate (CPF381);

5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(ethoxy- L -alaninyl)]phosphate (CPF383);

5-Fluoro-2′deoxyuridine-5′-O-[phenyl(isopropoxy- L -alaninyl)]phosphate (CPF384);

5-Fluoro-2′deoxyuridine-5′-O-[phenyl(cyclohexoxy- L -alaninyl)]phosphate (CPF508);

5-Fluoro-2′deoxyuridine-5′-O-[p-nitro-phenyl(ethoxy- L -alaninyl)]phosphate (CPF430);